Computational Biomodeling: Transforming Drug Design with Advanced Simulations

Year : 2024 | Volume : 13 | Issue : 03 | Page : 24 29
    By

    Aashish Verma,

  1. Student, B.Tech. in Biotechnology, Khwaja Moinuddin Chishti Language University, Lucknow, Uttar Pradesh, India

Abstract

Computational biomodeling has emerged as a transformative approach in the field of drug discovery, significantly enhancing the efficiency and precision of identifying and optimizing potential drug candidates. This article explores the various computational techniques utilized in drug design, including molecular docking, molecular dynamics (MD) simulations, free energy calculations, and virtual screening, and examines how these methods collectively contribute to the drug development process. The integration of these advanced simulations allows researchers to predict the interactions between small molecules (ligands) and target proteins, providing valuable insights into binding affinity, stability, and the overall likelihood of therapeutic efficacy. Molecular docking plays a pivotal role by predicting how a ligand interacts with a protein’s active site, while MD simulations provide a dynamic view of the ligand-protein interactions, highlighting their stability over time. Free energy calculations further complement these techniques by quantifying the strength of binding interactions, and virtual screening accelerates the identification of promising compounds from large chemical libraries. These methods work synergistically to refine drug candidates, optimizing their binding properties, bioavailability, and minimizing toxicity. One of the key advantages of computational biomodeling is the reduction in time and cost traditionally associated with experimental drug discovery. By narrowing down the most promising candidates early in the process, researchers can focus on those with the highest potential for success, thus increasing the probability of advancing lead compounds to preclinical and clinical testing. Furthermore, computational methods allow for the virtual testing of compounds for new therapeutic indications through drug repurposing, offering an additional route for discovering novel treatments. However, despite its successes, computational biomodeling faces challenges, such as data quality, the complexity of biological systems, and the need for substantial computational resources. Despite these limitations, the field continues to evolve, integrating emerging technologies like artificial intelligence (AI) and quantum computing, which promise to further enhance predictive accuracy and simulation efficiency. As these tools continue to develop, computational biomodeling holds great promise in accelerating the development of personalized, effective therapies for a wide range of diseases, marking a new era in drug discovery. In conclusion, computational biomodeling offers an invaluable approach to drug design, providing a more targeted, efficient, and cost-effective strategy to identify, optimize, and evaluate potential drug candidates in the modern pharmaceutical landscape.

Keywords: Computational biomodeling, drug discovery, molecular dynamics, ligand-protein interactions, artificial intelligence

[This article belongs to Research & Reviews : Journal of Computational Biology ]

How to cite this article:
Aashish Verma. Computational Biomodeling: Transforming Drug Design with Advanced Simulations. Research & Reviews : Journal of Computational Biology. 2024; 13(03):24-29.
How to cite this URL:
Aashish Verma. Computational Biomodeling: Transforming Drug Design with Advanced Simulations. Research & Reviews : Journal of Computational Biology. 2024; 13(03):24-29. Available from: https://journals.stmjournals.com/rrjocb/article=2024/view=190296


References

1. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Current computer-aided drug design. 2011 Jun 1;7(2):146–57.
2. Volkamer A, Kuhn D, Rippmann F, Rarey M. DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment. Bioinformatics. 2012 Aug 1;28(15):2074–5. doi: 10.1093/bioinformatics/bts310.
3. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem. 2005 Dec;26(16):1701–18. doi: 10.1002/jcc.20291.
4. Durrant JD, McCammon JA. Molecular dynamics simulations and drug discovery. BMC Biol. 2011;9(71). doi: 10.1186/1741-7007-9–71.
5. Kollman PA, Massova I, Diminich J. Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. AccChem Res. 2000;33(11):889–97.
6. Geary N. Understanding synergy. American J Physio-Endocrin Metabol. 2013 Feb 1;304(3):E237–53.
7. Mukherjee S, Saha A. Molecular modeling studies of estrogen receptor modulators. Current Computer-Aided Drug Design. 2006 Sep 1;2(3):229–53.
8. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature. 2004 Dec 16;432(7019):855–61.
9. Sliwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods in drug discovery. Pharmaco Revw. 2014 Jan 1;66(1):334–95.
10. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Compu Chem. 1998 Nov 15;19(14):1639–62.
11. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucle Acid Res. 2000 Jan 1;28(1):235–42.
12. Wilson GL, Lill MA. Integrating structure-based and ligand-based approaches for computational drug design. Future Med Chem. 2011 Apr 1;3(6):735–50.
13. Bekker GJ, Yokochi M, Suzuki H, Ikegawa Y, Iwata T, Kudou T, Yura K, Fujiwara T, Kawabata T, Kurisu G. Protein Data Bank Japan: Celebrating our 20th anniversary during a global pandemic as the Asian hub of three dimensional macromolecular structural data. Protein Science. 2022 Jan;31(1):173–86.
14. Srivastava S, Jain P. Computational Approaches: A New Frontier in Cancer Research. Combinatorial Chem High Thrghput Screen. 2024 Aug 1;27(13):1861–76.
15. Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020 Mar 18;25(6):1375.

Regular Issue Subscription Review Article
Volume 13
Issue 03
Received 27/11/2024
Accepted 02/12/2024
Published 19/12/2024
331

Login


My IP

PlumX Metrics